114 related articles for article (PubMed ID: 26305064)
1. Long-Term Response to Cholinesterase Inhibitor Treatment Is Related to Functional MRI Response in Alzheimer's Disease.
Miettinen PS; Jauhiainen AM; Tarkka IM; Pihlajamäki M; Gröhn H; Niskanen E; Hänninen T; Vanninen R; Soininen H
Dement Geriatr Cogn Disord; 2015; 40(5-6):243-55. PubMed ID: 26305064
[TBL] [Abstract][Full Text] [Related]
2. Effect of cholinergic stimulation in early Alzheimer's disease - functional imaging during a recognition memory task.
Miettinen PS; Pihlajamäki M; Jauhiainen AM; Tarkka IM; Gröhn H; Niskanen E; Hänninen T; Vanninen R; Soininen H
Curr Alzheimer Res; 2011 Nov; 8(7):753-64. PubMed ID: 21592058
[TBL] [Abstract][Full Text] [Related]
3. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease.
Rombouts SA; Barkhof F; Van Meel CS; Scheltens P
J Neurol Neurosurg Psychiatry; 2002 Dec; 73(6):665-71. PubMed ID: 12438467
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.
Cagnin A; Cester A; Costa B; Ermani M; Gabelli C; Gambina G;
Neurol Sci; 2015 Mar; 36(3):457-63. PubMed ID: 25394739
[TBL] [Abstract][Full Text] [Related]
5. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study.
Goekoop R; Scheltens P; Barkhof F; Rombouts SA
Brain; 2006 Jan; 129(Pt 1):141-57. PubMed ID: 16251213
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
7. Treatment effects of therapeutic cholinesterase inhibitors on visuospatial processing in Alzheimer's disease: a longitudinal functional MRI study.
Thiyagesh SN; Farrow TF; Parks RW; Accosta-Mesa H; Hunter MD; Young C; Wilkinson ID; Woodruff PW
Dement Geriatr Cogn Disord; 2010; 29(2):176-88. PubMed ID: 20215749
[TBL] [Abstract][Full Text] [Related]
8. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
9. Neurophysiological predictors of long term response to AChE inhibitors in AD patients.
Di Lazzaro V; Oliviero A; Pilato F; Saturno E; Dileone M; Marra C; Ghirlanda S; Ranieri F; Gainotti G; Tonali P
J Neurol Neurosurg Psychiatry; 2005 Aug; 76(8):1064-9. PubMed ID: 16024879
[TBL] [Abstract][Full Text] [Related]
10. Attenuation of functional hyperemia to visual stimulation in mild Alzheimer's disease and its sensitivity to cholinesterase inhibition.
Janik R; Thomason LA; Chaudhary S; Dorr A; Scouten A; Schwindt G; Masellis M; Stanisz GJ; Black SE; Stefanovic B
Biochim Biophys Acta; 2016 May; 1862(5):957-65. PubMed ID: 26521151
[TBL] [Abstract][Full Text] [Related]
11. Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer's disease.
Droogsma E; van Asselt D; Diekhuis M; Veeger N; van der Hooft C; De Deyn PP
Int Psychogeriatr; 2015 Aug; 27(8):1323-33. PubMed ID: 25779465
[TBL] [Abstract][Full Text] [Related]
12. Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
Kadir A; Darreh-Shori T; Almkvist O; Wall A; Långström B; Nordberg A
Psychopharmacology (Berl); 2007 May; 191(4):1005-14. PubMed ID: 17310387
[TBL] [Abstract][Full Text] [Related]
13. Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer's disease.
Richter N; Beckers N; Onur OA; Dietlein M; Tittgemeyer M; Kracht L; Neumaier B; Fink GR; Kukolja J
Brain; 2018 Mar; 141(3):903-915. PubMed ID: 29309600
[TBL] [Abstract][Full Text] [Related]
14. Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study.
Bokde AL; Karmann M; Teipel SJ; Born C; Lieb M; Reiser MF; Möller HJ; Hampel H
J Clin Psychopharmacol; 2009 Apr; 29(2):147-56. PubMed ID: 19512976
[TBL] [Abstract][Full Text] [Related]
15. Effects of cholinesterase inhibitor on brain activation in Alzheimer's patients measured with functional near-infrared spectroscopy.
Metzger FG; Ehlis AC; Haeussinger FB; Fallgatter AJ; Hagen K
Psychopharmacology (Berl); 2015 Dec; 232(23):4383-91. PubMed ID: 26359227
[TBL] [Abstract][Full Text] [Related]
16. Responders to ChEI treatment of Alzheimer's disease show restitution of normal regional cortical activation.
Venneri A; McGeown WJ; Shanks MF
Curr Alzheimer Res; 2009 Apr; 6(2):97-111. PubMed ID: 19355844
[TBL] [Abstract][Full Text] [Related]
17. Effects of rivastigmine on visual attention in subjects with amnestic mild cognitive impairment: A serial functional MRI activation pilot-study.
Bokde AL; Cavedo E; Lopez-Bayo P; Lista S; Meindl T; Born C; Galluzzi S; Faltraco F; Dubois B; Teipel SJ; Reiser M; Möller HJ; Hampel H
Psychiatry Res Neuroimaging; 2016 Mar; 249():84-90. PubMed ID: 26851974
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
Crowell TA; Paramadevan J; Abdullah L; Mullan M
J Geriatr Psychiatry Neurol; 2006 Mar; 19(1):13-5. PubMed ID: 16449754
[TBL] [Abstract][Full Text] [Related]
19. Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease: preliminary findings from a pharmaco-fMRI study.
Kircher TT; Erb M; Grodd W; Leube DT
Am J Geriatr Psychiatry; 2005 Nov; 13(11):1006-13. PubMed ID: 16286445
[TBL] [Abstract][Full Text] [Related]
20. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
